Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC

July 14, 2026 9:16 AM

Biogen presented Phase 2 CELIA study data on diranersen, an investigational antisense oligonucleotide therapy targeting tau protein, at the Alzheimer's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found